AVITA Medical, Inc. (RCEL) Misses Q3 EPS by 19c, provides guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q3 EPS of ($0.62), $0.19 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $19.55 million versus the consensus estimate of $19.44 million.

GUIDANCE:

AVITA Medical, Inc. sees Q4 2024 revenue of $22.3-24.3 million, versus the consensus of $23.516 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)